Biomarkers

A special series of articles discussing challenges and opportunities in the discovery, validation and application of biomarkers.


Top

2010

March 2012 Vol 11 No 3

Cancer biomarkers: selecting the right drug for the right patient

Gary J. Kelloff & Caroline C. Sigman

doi:10.1038/nrd3651

Top

2010

July 2010 Vol 9 No 7

Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives

Harald Hampel, Richard Frank, Karl Broich, Stefan J. Teipel, Russell G. Katz, John Hardy, Karl Herholz, Arun L. W. Bokde, Frank Jessen, Yvonne C. Hoessler, Wendy R. Sanhai, Henrik Zetterberg, Janet Woodcock & Kaj Blennow

doi:10.1038/nrd3115

Top

2008

January 2008 Vol 7 No 1

Neurophysiological biomarkers for drug development in schizophrenia

Daniel C. Javitt, Kevin M. Spencer, Gunvant K. Thaker, Georg Winterer & Mihály Hajós

doi:10.1038/nrd2463

Top

2007

April 2007 Vol 6 No 4

Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers

Mark R. Trusheim, Ernst R. Berndt and Frank L. Douglas

p287 | doi:10.1038/nrd2251

April 2007 Vol 6 No 4

Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics

Leslie M. Shaw, Magdalena Korecka, Christopher M. Clark, Virginia M.–Y. Lee and John Q. Trojanowski

p295 | doi:10.1038/nrd2176

Top

2006

June 2006 Vol 5 No 6

Diagnostics and biomarker development: priming the pipeline

Kathryn A. Phillips, Stephanie Van Bebber and Amalia M. Issa

p463 | doi:10.1038/nrd2033

Application of intravascular ultrasound in anti-atherosclerotic drug development

Stephen J. Nicholls, Ilke Sipahi, Paul Schoenhagen, Tim Crowe, E. Murat Tuzcu and Steven E. Nissen

p485 | doi:10.1038/nrd2040

May 2006 Vol 5 No 5

A role for fMRI in optimizing CNS drug development

David Borsook, Lino Becerra and Richard Hargreaves

p411 | doi:10.1038/nrd2027

April 2006 Vol 5 No 4

Multiplexed protein measurement: technologies and applications of protein and antibody arrays

Stephen F. Kingsmore

p310 | doi:10.1038/nrd2006

Top